Search results for "coagulation"

showing 10 items of 381 documents

Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer

2012

Cancer-related disseminated intravascular coagulation (DIC) is a life-threatening condition for which no effective treatment is currently available. Protein C (PC), a modulator of coagulation as well as the inflammatory system, has been successfully tested (in its activated recombinant form [a-rPC]) in sepsis-related coagulopathy, but with an increased risk for major bleeding. Plasma-derived PC (pd-PC) is more suitable than a-rPC in patients at high risk from bleeding due to its self-limiting process. We carried out a single-arm study evaluating the role of pd-PC in adult cancer patients with overt DIC. Over a period of 3 years, we treated 19 patients with overt DIC and a PC plasma concentr…

AdultMalemedicine.medical_specialtyGastroenterologySettore MED/15 - Malattie Del SangueNeoplasmsInternal medicineCoagulopathymedicineHumansBlood Coagulationdisseminated intravascular coagulationSurvival analysisAgedAged 80 and overDisseminated intravascular coagulationHematologic Testsbusiness.industryPlasma derivedAnticoagulantsCancerHematologyMiddle Agedmedicine.diseaseSurvival AnalysisThrombosisSurgeryCoagulationFemalebusinessProtein CProtein Cmedicine.drugAmerican Journal of Hematology
researchProduct

Pain-induced alterations in the individual non-esterified fatty acids in serum.

1979

Changes of individual non-esterified fatty acids in serum were studied in 7 metabolically healthy patients, suffering from idiopathic trigeminal neuralgia, who underwent electrocoagulation of gasserian ganglion under neurolepthypalgesia. The mean concentration of fatty acids increased by about 40% during the strong surgical pain stimulus. The increased lipolysis affected all individual fatty acids in proportion to the ratio of their presence in adipose tissue. The mechanism of pain-induced activation of lipase and possible consequences of alterations in individual non-esterified fatty acids are discussed.

AdultMalemedicine.medical_specialtyIncreased LipolysisAdipose tissueBiologyFatty Acids NonesterifiedTrigeminal ganglionTrigeminal neuralgiaInternal medicinemedicineIdiopathic trigeminal neuralgiaElectrocoagulationHumansLipaseAgedchemistry.chemical_classificationLipid MobilizationFatty acidMiddle AgedTrigeminal Neuralgiamedicine.diseaseGanglionAnesthesiology and Pain MedicineEndocrinologymedicine.anatomical_structureNeurologychemistryTrigeminal Ganglionbiology.proteinFemaleNeurology (clinical)Pain
researchProduct

Association between platelet glycoprotein Ib-alpha and myocardial infarction: results of a pilot study performed in male and female patients from Sic…

2007

Myocardial infarction (AMI) is a complex multifactorial disorder. Platelet adhesion and thrombosis are pivotal events in the development of atherosclerotic lesions. Occlusive thrombus is almost exclusively initiated by plaque rupture and adhesion of platelets to subendothelial von Willebrand factor (vWf) by its specific platelet receptor, the alpha-chain of glycoprotein (GP) Ib-IX-V complex of the human platelet-specific antigens (HPA). Two polymorphisms have been reported in the sequence of GPIb-alpha. The first, a C/T transition at nucleotide 1018 results in an amino acid dimorphism (Thr/Met) at residue 145 of GPIb-alpha, which is located within the vWF-binding domain of the receptor. The…

AdultMalemedicine.medical_specialtyKozak consensus sequenceMyocardial InfarctionPilot ProjectsPlatelet membrane glycoproteinGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceAntigenVon Willebrand factorGene FrequencyPolymorphism (computer science)Internal medicinevon Willebrand FactormedicineHumansPlateletSicilyAllelesPolymorphism Geneticbiologybusiness.industryGeneral NeurosciencePlatelet Glycoprotein GPIb-IX ComplexMiddle AgedEndocrinologyCoagulationPlatelet Glycoprotein GPIb-IX ComplexCase-Control StudiesImmunologybiology.proteinFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

Endovenous treatment of the great saphenous vein using a 1,320 nm Nd:YAG laser causes fewer side effects than using a 940 nm diode laser.

2005

Limited data are available about treatment-related side effects with respect to laser wavelength in endovenous laser treatment (ELT) of the great saphenous vein (GSV).To compare the results and side effects of a 940 nm diode and a 1,320 nm neodymium:yttium-aluminum-garnet (Nd:YAG) laser.Three patient cohorts (A, B, and C) received ELT of the GSV using a 940 nm diode laser at 15 W (group A) or 30 W (group B) or using a 1,320 nm laser at 8 W (group C). In all cases, energy was administered continuously with constant pullback of the laser fiber under perivenous tumescent local anesthesia.The GSVs of group A (n = 113), group B (n = 136), and group C (n = 33) received ELT. An average linear endo…

AdultMalemedicine.medical_specialtyMaterials scienceAdolescentmedicine.medical_treatmentTreatment outcomechemistry.chemical_elementDermatologyNeodymiumlaw.inventionlawmedicineHumansSaphenous VeinDiodeAgedRetrospective StudiesAged 80 and overLaser Coagulationbusiness.industryGreat saphenous veinEndovenous laser treatmentGeneral MedicineMiddle AgedLaserSurgeryChronic diseaseTreatment OutcomechemistryVenous InsufficiencyNd:YAG laserChronic DiseaseSurgeryFemaleNuclear medicinebusinessDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
researchProduct

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation

2006

Aims To describe guideline adherence and application of different stroke risk stratification schemes regarding antithrombotic therapy in real-life atrial fibrillation (AF) patients and to assess which factors influence antithrombotic management decisions. Methods and results The Euro Heart Survey enrolled 5333 AF patients in 35 countries, in 2003 and 2004. Prescription of antithrombotic drugs, especially oral anticoagulation (OAC), was hardly tailored to the patient's stroke risk profile as indicated by the joint guidelines of the American College of Cardiology, American Heart Association, and the European Society of Cardiology, ACCP guidelines, or CHADS2 and Framingham risk scores. In mult…

AdultMalemedicine.medical_specialtyOral anticoagulationGuidelineRisk AssessmentElectrocardiographyFibrinolytic AgentsRisk FactorsDrug CombinationAntithromboticmedicineHumansOutpatient clinicRisk factorMultivariate AnalysiStrokeRisk stratificationAgedAntithrombotic therapyFibrinolytic AgentFramingham Risk Scorebusiness.industryRisk FactorAtrial fibrillationMiddle Agedmedicine.diseaseAtrial fibrillationStrokeDrug CombinationsMultivariate AnalysisPractice Guidelines as TopicEmergency medicinePhysical therapyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessCardioversionsRisk assessmentHumanEuropean Heart Journal
researchProduct

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1993

We have measured various fibrinolytic and coagulation parameters (t-PA antigen, PAI, fibrinogen, plasminogen and factor VII) before and after 10 min of venous occlusion in 20 hypertryglyceridaemic subjects (twelve males and eight females, age 38 +/- 4 years, body mass index 23 +/- 1.5) and 20 healthy normal subjects, matched for sex (twelve males and eight females), age (37 +/- 3.5 years) and body mass index (22.8 +/- 1.4). At rest, t-PA:Ag, PAI, fibrinogen, plasminogen and factor VII were significantly (P < 0.005) higher in hypertriglyceridaemic subjects than in normal controls. After venous occlusion, the increase in all parameters except t-PA:Ag was more marked in the patient group than …

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentFibrinogenHyperlipoproteinemia Type IVVeinschemistry.chemical_compoundAntigenInternal medicineOcclusionFibrinolysisPlasminogen Activator Inhibitor 1medicineHumansFactor VIIbusiness.industryFibrinolysisHypertriglyceridemiaFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseConstrictionLipidsEndocrinologyApolipoproteinsCoagulationchemistryTissue Plasminogen ActivatorFemalebusinessBody mass indexmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Spontaneous chronic subdural hematomas in young adults with a deficiency in coagulation factor XIII. Report of three cases

2005

✓ Chronic subdural hematomas (SDHs) generally occur in elderly patients. Its pathogenesis is usually related to head trauma with tearing and rupture of the bridging veins, although in some cases a history of trauma is not recognizable. There are many reports regarding the association between spontaneous chronic SDHs and an alteration in coagulative parameters. A coagulative disorder should be suspected when an unexplained hemorrhage occurs, especially in a young patient. The authors report on three young men with a deficiency in coagulation factor XIII (FXIII) who underwent surgery for chronic SDHs. The role of FXIII in the pathogenesis of chronic SDH is emphasized. In patients with unexpla…

AdultMalemedicine.medical_specialtyPediatricsCoagulation Factor Deficiencysubdural hematornaHead traumacoagulopathyPathogenesisHematomamedicineCoagulopathyHumansPostoperative CareVascular diseasebusiness.industryHeadachefactor XIIIFactor XIIImedicine.diseaseFactor XIII DeficiencyMagnetic Resonance ImagingSurgeryCoagulative necrosisHematoma Subdural Chronicbusinessmedicine.drug
researchProduct

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patient…

2008

We recommend prophylaxis in haemophilic children with an inhibitor as a way of preventing the musculoskeletal impairment that is likely to affect them. This approach has been used for children without inhibitors with excellent results. If prophylaxis is not feasible, we suggest that intensive on-demand treatment should be given. Two agents, recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCC), are currently used to control haemostasis either for prophylaxis or intensive on-demand treatment. As it is recombinant, rFVIIa would seem more appropriate to be employed in children. aPCC could be used in adults, or in the event of an unsatisfactory response to rF…

AdultMalemedicine.medical_specialtyPediatricsTime FactorsEvidence-based practiceAdolescentFactor VIIaHemophilia AHaemophiliaFactor IXYoung AdultHemarthrosismedicineOrthopaedic proceduresHumansPain ManagementOrthopedic ProceduresChildIntensive care medicinePhysical Therapy ModalitiesGenetics (clinical)Randomized Controlled Trials as TopicRetrospective StudiesHaemophilic arthropathySynovitisBlood Coagulation Factor InhibitorsCoagulantsbusiness.industryMusculoskeletal impairmentHematologyGeneral MedicinePerioperativemedicine.diseaseSkeletal maturityBlood Coagulation FactorsRecombinant ProteinsCartilageTreatment OutcomeChild PreschoolPractice Guidelines as TopicbusinessPROTHROMBIN COMPLEXHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Retinal vascular occlusion and deficiencies in the protein C pathway.

1999

Abstract PURPOSE: To report abnormalities in the protein C pathway and other vascular occlusion risk factors in patients with retinal vascular occlusion. METHODS: In a study, we investigated 76 consecutive patients who had in-patient evaluation of venous or arterial retinal vascular occlusion. All patients underwent comprehensive tests for coagulation disorders including determinations of protein C, protein S, lupus anticoagulants, and resistance to activated protein C and were screened for vascular disease risk factors. Resistance to activated protein C was confirmed by a polymerase chain reaction method to detect the specific factor V R506Q mutation. For comparative purposes, we also scre…

AdultMalemedicine.medical_specialtyRetinal Artery OcclusionDeep veinVascular occlusionGastroenterologyProtein SProtein SCentral retinal vein occlusionRisk FactorsInternal medicineRetinal Vein OcclusionmedicinePrevalenceHumansProspective StudiesActivated Protein C ResistanceAgedRetinal Vascular OcclusionAged 80 and overbiologybusiness.industryFactor VFactor VProtein C DeficiencyMiddle Agedmedicine.diseaseThrombosisSurgeryOphthalmologymedicine.anatomical_structureLupus Coagulation InhibitorMutationbiology.proteinBranch retinal vein occlusionFemalemedicine.symptombusinessProtein CAmerican journal of ophthalmology
researchProduct